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The nitric oxide (NO)/cyclic GMP signaling system regu-
lates both vascular and cardiac function in fundamental
ways. Vascular tone is dynamically regulated by vascular
smooth muscle cell contractile state. The main effector of
NO/cGMP action in cardiovascular target tissues is cyclic
GMP-dependent protein kinase I (PKG), a cGMP-acti-
vated serine-threonine kinase with multiple targets in vas-
cular and cardiac cells. In the vasculature, the NO/cGMP/
PKG signaling system is the most important endogenous
vasodilator system known. Vascular contraction by many
agonists is mediated by Gq-coupled receptor activation,
calcium mobilization and myosin light chain (MLC)
phosphorylation. Nitric oxide (NO) inhibits vascular con-
traction by activating PKGIα, which both attenuates cal-
cium mobilization by GPCR and activates myosin
phosphatase (PP1M), causing dephosphorylation of
myosin light chain and VSMC relaxation. We have shown
that PKGIα binds directly to the MBS subunit of the PP1M
phosphatase. PKGIα also attenuates signaling by Gq-cou-
pled receptors via a direct interaction with the regulator of
G-protein signaling, RGS2, which PKGI phosphorylates
and activates to terminate Gq-coupled receptor-mediated
signaling. The N-terminal leucine zipper (LZ) of PKGIα
mediates its interaction with PP1M and RGS2. To explore
the role of PKGIα in blood vessels and heart, we used gene
targeting several years ago to create mice that express a LZ
mutant (LZM) form of PKGIα in which critical amino
acids in the leucine zipper motif have been substituted to
disrupt LZ binding. Newer studies of these mice will be
described. VSMC from PKGIα mutant mice display multi-
ple phenotypic abnormalities in culture. In addition,
PKGIα-mediated regulation of Rho/Rho kinase signaling
is disrupted in intact VSMC from LZM mice. Blood vessels
from PKG1α mutant mice relax abnormally and intact
PKG1α mutant mice have systemic hypertension, without
detectable abnormalities of renal function. New data
regarding PKGIα and myocardial function in wild type
and LZM mice will also be discussed. These data demon-
strate the central importance of PKGIα signaling in main-
tenance of normal vascular physiology and blood
pressure, and in the regulation of myocardial hypertro-
phy.
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